The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated

Plater-Zyberk, C; Estêvão, Dave M. Lopes; d’Argouges, Sandrine; Haanstra, Krista G.; Kondova, Ivanela; Vierboom, Michel; Boehm, Thomas; Neef, Ruediger; Vieser, Eva; Rattel, Benno; Baeuerle, Patrick A.; Jonker, Margreet

doi:10.1016/j.trim.2011.06.003

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second study describes a pilot study to set up an Alzheimer’s disease model in marmosets (50). Other research themes were understanding disease mechanisms and refinement of immunosuppression, yielding four publications (43–46, 49). …”

Section: Achievementsmentioning

confidence: 99%

See 1 more Smart Citation

An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates

2016

Self Cite

View full text Add to dashboard Cite

Aging western societies are facing an increasing prevalence of chronic inflammatory and degenerative diseases for which often no effective treatments exist, resulting in increasing health-care expenditure. Despite high investments in drug development, the number of promising new drug candidates decreases. We propose that preclinical research in non-human primates can help to bridge the gap between drug discovery and drug prescription. Translational research covers various stages of drug development of which preclinical efficacy tests in valid animal models is usually the last stage. Preclinical research in non-human primates may be essential in the evaluation of new drugs or therapies when a relevant rodent model is not available. Non-human primate models for life-threatening or severely debilitating diseases in humans are available at the Biomedical Primate Research Centre (BPRC). These have been instrumental in translational research for several decades. In order to stimulate European health research and innovation from bench to bedside, the European Commission has invested heavily in access to non-human primate research for more than 20 years. BPRC has hosted European users in a series of transnational access programs covering a wide range of research areas with the common theme being immune-mediated inflammatory disorders. We present an overview of the results and give an account of the studies performed as part of European Union Framework Programme (EU FP)-funded translational non-human primate research performed at the BPRC. These data illustrate the value of translational non-human primate research for the development of new therapies and emphasize the importance of EU FP funding in drug development.

show abstract

Section: Achievementsmentioning

confidence: 99%

“…Amgen has bought Micromet, the company that developed the anti-IL2 receptor monoclonal antibody developed (46). Whether this antibody is still under development by Amgen has not been disclosed on the AMGEN website.…”

Section: Translational Value Of Executed Projectsmentioning

confidence: 99%